Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Long-Term Deferred Tax: 2009-2024

Historic Long-Term Deferred Tax for Gyre Therapeutics (GYRE) over the last 5 years, with Dec 2024 value amounting to $5.6 million.

  • Gyre Therapeutics' Long-Term Deferred Tax rose 30.09% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 30.09%. This contributed to the annual value of $5.6 million for FY2024, which is 19.68% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Long-Term Deferred Tax of $5.6 million as of FY2024, which was up 19.68% from $4.7 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Long-Term Deferred Tax ranged from a high of $5.6 million in FY2024 and a low of $4.1 million during FY2022.
  • Its 3-year average for Long-Term Deferred Tax is $4.8 million, with a median of $4.7 million in 2023.
  • Data for Gyre Therapeutics' Long-Term Deferred Tax shows a peak YoY increased of 19.68% (in 2024) over the last 5 years.
  • Over the past 3 years, Gyre Therapeutics' Long-Term Deferred Tax (Yearly) stood at $4.1 million in 2022, then rose by 15.05% to $4.7 million in 2023, then rose by 19.68% to $5.6 million in 2024.